Cargando…

A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone

Validated biomarkers are needed to improve risk assessment and treatment decision-making for women with ductal carcinoma in situ (DCIS) of the breast. The Oncotype DX(®) DCIS Score (DS) was shown to predict the risk of local recurrence (LR) in individuals with low-risk DCIS treated by breast-conserv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rakovitch, Eileen, Nofech-Mozes, Sharon, Hanna, Wedad, Baehner, Frederick L., Saskin, Refik, Butler, Steven M., Tuck, Alan, Sengupta, Sandip, Elavathil, Leela, Jani, Prashant A., Bonin, Michel, Chang, Martin C., Robertson, Susan J., Slodkowska, Elzbieta, Fong, Cindy, Anderson, Joseph M., Jamshidian, Farid, Miller, Dave P., Cherbavaz, Diana B., Shak, Steven, Paszat, Lawrence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491104/ https://www.ncbi.nlm.nih.gov/pubmed/26119102 http://dx.doi.org/10.1007/s10549-015-3464-6

Ejemplares similares

Close or positive resection margins are not associated with an increased risk of chest wall recurrence in women with DCIS treated by mastectomy: a population-based analysis
por: Klein, Jonathan, et al.
Publicado: (2015)

Biological Markers Predictive of Invasive Recurrence in DCIS
por: Nofech-Mozes, Sharon, et al.
Publicado: (2008)

Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?
por: Hahn, Ezra, et al.
Publicado: (2023)

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
por: Rakovitch, E., et al.
Publicado: (2018)

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
por: Rakovitch, E, et al.
Publicado: (2012)

Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score
por: Lalani, Nafisha, et al.
Publicado: (2017)

Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast
por: Jia, Huiqing, et al.
Publicado: (2022)

Intraoperative Assessment of Sentinel Lymph Nodes in Breast Cancer Patients Post-Neoadjuvant Therapy
por: Wong, Willard, et al.
Publicado: (2019)

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy
por: van Roozendaal, L. M., et al.
Publicado: (2016)

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831
por: Perez, Edith A., et al.
Publicado: (2015)

Evaluation of a clinical risk index for advanced colorectal neoplasia among a North American population of screening age
por: Ruco, Arlinda, et al.
Publicado: (2015)

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance
por: Viale, Giuseppe, et al.
Publicado: (2016)

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors
por: Sestak, Ivana, et al.
Publicado: (2016)

Countercurrents: DCIS or Cancer? Why All the Confusion?
por: Narod, Steven A., et al.
Publicado: (2022)

Is palpable DCIS more aggressive than screen-detected DCIS?
por: Balac, Nina, et al.
Publicado: (2022)

Common genetic susceptibility to DCIS and invasive ductal carcinoma
por: Sopik, Victoria, et al.
Publicado: (2016)

Borderline Phyllodes Tumor with an Incidental Invasive Tubular Carcinoma and Lobular Carcinoma In Situ Component: A Case Report
por: Quinlan-Davidson, Sean, et al.
Publicado: (2011)

Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)
por: Wärnberg, Fredrik, et al.
Publicado: (2021)

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2018)

Ductal carcinoma in situ (DCIS)
por: Holland, R
Publicado: (2002)

Imaging features of noncalcified DCIS
por: Scudder, JM, et al.
Publicado: (2012)

61. EXPRESSION OF ANDROGEN RECEPTOR IN BREAST CANCER BRAIN METASTASIS
por: Qazi, Maleeha, et al.
Publicado: (2020)

Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions
por: Bergholtz, Helga, et al.
Publicado: (2020)

Ductal Carcinoma In Situ (DCIS) and Microinvasive DCIS: Role of Surgery in Early Diagnosis of Breast Cancer
por: Magnoni, Francesca, et al.
Publicado: (2023)

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
por: Nitz, Ulrike, et al.
Publicado: (2017)

Increasing research capacity with ICES Data & Analytic Services (DAS)
por: Ishiguro, Lisa, et al.
Publicado: (2017)

A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay
por: Lei, Rachel Y., et al.
Publicado: (2020)

MLH1 Methylation Testing as an Integral Component of Universal Endometrial Cancer Screening—A Critical Appraisal
por: Plotkin, Anna, et al.
Publicado: (2023)

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
por: Iwata, Hiroji, et al.
Publicado: (2018)

Boost und Hypofraktionierung beim DCIS
por: Dunst, Jürgen, et al.
Publicado: (2022)

A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
por: Solin, Lawrence J., et al.
Publicado: (2013)

Low-acuity emergency department use among patients in different primary care models in Hamilton and Ontario
por: Ly, Olivia, et al.
Publicado: (2021)

Pan-cancer classification of single cells in the tumour microenvironment
por: Nofech-Mozes, Ido, et al.
Publicado: (2023)

Assessment of Secondary Sarcomas Among Patients With Cancer of the Abdomen or Pelvis Who Received Combinations of Surgery, Radiation, and Chemotherapy vs Surgery Alone
por: Hird, Amanda E., et al.
Publicado: (2020)

The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS
por: Wallis, M G, et al.
Publicado: (2012)

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer
por: Mostafid, A. Hugh, et al.
Publicado: (2020)

A review and comparison of breast tumor cell nuclei segmentation performances using deep convolutional neural networks
por: Lagree, Andrew, et al.
Publicado: (2021)

A Cluster-then-label Semi-supervised Learning Approach for Pathology Image Classification
por: Peikari, Mohammad, et al.
Publicado: (2018)

Ductal carcinoma in situ (DCIS): are we overdetecting it?
por: Evans, A
Publicado: (2004)

Ductal carcinoma in situ (DCIS): are we overtreating it?
por: Dixon, JM
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_8ur0dp1rugklimdbm5gnsfrp3j